CRISIL Reaffirms and Withdraws Key Debt Ratings for Mankind Pharma
Mankind Pharma Ltd · Others (Uncategorized) · 30 Oct 2026, 1:56 am
CRISIL Reaffirms and Withdraws Key Debt Ratings for Mankind Pharma On 29th Oct'26, CRISIL Ratings reaffirmed its 'CRISIL AA+/Stable' rating on Mankind Pharma Limited’s Non-Convertible Debentures (NCDs) worth ₹400 crore and ₹2,100 crore. Simultaneously, the agency withdrew its 'CRISIL AA+/Stable' rating on NCDs amounting to ₹2,500 crore and its 'CRISIL A1+' rating on Commercial Paper totaling ₹1,500 crore.
Original exchange filing (PDF)
More announcements from Mankind Pharma Ltd
- Please find attached intimation regarding change in Corporate Office Address of RTA · 13 Nov 2026
- Please find attached Intimation of participation in the Investor Conference · 06 Nov 2026
- Please find attached intimation regarding ESG Rating · 05 Nov 2026
- Intimation of participation in the Investor Conference. · 03 Nov 2026
- Please find attached transcript of the Earnings Conference Call for Q2 & H1 FY27 · 30 Oct 2026
- In continuation of our earlier intimation dated October 22, 2026 please find attached the Investor Presentation to be made during the said Analyst / Institutional Investors meet · 27 Oct 2026
- Please find attached link for audio recording of the Investor Conference Call held on October 26, 2026 · 27 Oct 2026
- Investor Presentation on Financial Results of the Company for Q2 & H1FY27 · 26 Oct 2026
